Literature DB >> 922670

Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication.

J S Meyer, B R Rao, S C Stevens, W L White.   

Abstract

The results of assay for estrogen receptor (ER) in the tumor cytosol and thymidine labeling indices (TLI) of 63 primary invasive carcinomas of the breast were analyzed. The ER assay was performed by using dextran-charcoal to adsorb unbound tritiated estradiol-17beta (E2) in cytosol. The TLI was measured as the number per hundred of neoplastic cell nuclei labeled by tritiated thymidine. A significant association between low TLI and presence of ER was found. Wereas all 19 tumors with TLI less than 2.5 contained ER in the primary lesion or in axillary metastases and ER was found in 25 of 30 tumors with TLI between 2.5 and 10, only 4 of 14 tumors with TLI greater 10 contained ER (p less than 0.001). TLI and saturable binding of E2 were significantly negatively correlated (r=-0.436,P. less than 0.001). It is concluded that dedifferentiation in breast carcinomas is associated with both high TLI and absence of ER, and suggested that the carcinomas with the most rapid proliferative rates will include the highest proportion of tumors unresponsive to hormonal therapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 922670     DOI: 10.1002/1097-0142(197711)40:5<2290::aid-cncr2820400541>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  41 in total

Review 1.  [Current status in the treatment of breast cancer. I. Endocrine management--change of concepts and outlook for the future (author's transl)].

Authors:  U Jehn; H Sauer; W Wilmanns
Journal:  Klin Wochenschr       Date:  1979-09-17

2.  Prognostic significance of steroid hormone receptors and histopathological characterization of human breast cancer.

Authors:  A Reiner; R Kolb; G Reiner; R Jakesz; M Schemper; J Spona
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Nucleolar grading of breast cancer. Comparative studies on frequency and localization of nucleoli and histology, stage, hormonal receptor status and lectin histochemistry.

Authors:  B Helpap
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

Review 4.  Timing of dietary fat exposure and mammary tumorigenesis: role of estrogen receptor and protein kinase C activity.

Authors:  L Hilakivi-Clarke; R Clarke
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

Review 5.  Practical breast carcinoma cell kinetics: review and update.

Authors:  J S Meyer; R W McDivitt; K R Stone; M U Prey; W C Bauer
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

6.  Simultaneous and sequential determinations of steroid hormone receptors in human breast cancer. Influence of intervening therapy.

Authors:  R Jakesz; C Dittrich; J Hanusch; R Kolb; R Lenzhofer; K Moser; H Rainer; G Reiner; M Schemper; J Spona
Journal:  Ann Surg       Date:  1985-03       Impact factor: 12.969

7.  Multiple steroid receptors in human breast cancer. III. Relationships between steroid receptors and the state of differentiation and the activity of carcinomas throughout the pathologic features.

Authors:  P M Martin; P H Rolland; J Jacquemier; A M Rolland; M Toga
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

8.  A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer.

Authors:  J C Allegra; T M Woodcock; S P Richman; K I Bland; J L Wittliff
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

9.  Relationship between the content of estrogen and progesterone receptors and the pathological characteristics in human breast cancer.

Authors:  R Nishimura; A Misumi; M Kimura; T Tokunaga; M Akagi
Journal:  Jpn J Surg       Date:  1982

10.  The influence of estradiol and adriamycin on the RNA biosynthesis in breast cancer.

Authors:  P Schlag; J Veser; G Geier; D Breitig
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.